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Abstract
Background: At present, it is highly controversial whether pure mast cells can serve as antigen presenting cells, and it 
is not known whether the capacity of antigen presenting function is temporally restricted to a particular subset of 
differentiated mast cells. Evidence is presented for a novel surface FcεRIhi , MHC II +, and c-kit + pure mast cell subset, 
temporally restricted as antigen-presenting cells in the immune axis of T-cell activation.
Results: Bone marrow-derived mast cells (BMMC) cultured in the presence of IL-3 for three weeks are pure mast cells 
based on surface expression of lineage-specific marker, c-kit and FcεRI. Herein we present the first demonstration that 
approximately 98.7% c-kit + and FcεRI expressing BMMC, further depleted of any contaminated professional antigen-
presenting cells, are still fully capable of presenting antigens, i.e., OVA protein, OVA peptide, and IgE-TNP-OVA, to OVA 
peptide-specific T-cell hybridomas. Notably, IgE-dependent antigen presentation is more efficient compared to that 
resulting from direct antigen uptake. Importantly, we present the novel finding that only surface FcεRIhi mast cells, also 
expressing surface MHC II exhibited antigen-presenting function. In contrast, surface FcεRIlo mast cells without 
expressing surface MHC II were not capable of antigen presentation. Interestingly, the antigen-presenting function of 
BMMC was irrevocably lost during the third and fourth week in IL-3 or SCF containing cultures.
Conclusions: This is the first observation to attribute a spatiotemporally restricted antigen-presenting function to a 
subset of three-week old pure BMMC expressing both high levels of surface FcεRI and surface MHC II. We propose that 
mast cells play an important role in immune deviating and/or sustaining the activation of infiltrating CD4 T-cells, and 
modulating T-cell mediated allergic inflammation via its flexibility to present antigens and antigen-IgE complexes.
Background
Mast cells are traditionally thought of as a secretory cell
type releasing inflammatory mediators in IgE-dependent
inflammation[1,2]. Their role in innate immunity against
pathogens has been uncovered, which is associated with
their uptake and clearance of the microbes [3,4]. Mast
cells undergo maturation and specialization in different
tissue compartments [5-7]. Adoptively transferred pro-
genitors of mast cells from fetal liver and bone marrow
repopulate the skin and mucosa of intestine and lung in
mast cell-deficient mice as connective-tissue type as well
as mucosal type mast cells, distinguished by the granular
content and safranin-based staining [5-7].
Although early studies have shown that bone marrow-
derived mast cells (BMMC) are capable of presenting
bacterial and protein antigens via MHC class I and MHC
II pathways [8,9], the purity of mast cells used and
whether all BMMC are capable of antigen presentation
a r e  n o t  k n o w n .  H e r e i n ,  w e  s h o w e d  t h a t  c l o s e  t o  9 9 %
(98.7%) pure, c-kit + BMMC obtained by culturing bone
marrow cells in IL-3-containing medium for three-week,
followed by removal of putative contaminating antigen-
presenting cells (APC), are fully capable of antigen pre-
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sentation. Herein, we present a novel finding that only the
BMMC subset expressing high levels of FcεRI, concomi-
tantly with high levels of MHC II on the cell surface, is
capable of antigen presentation, whereas another BMMC
subset expressing low levels of surface FcεRI and no
detectable cell surface MHC II, fails to present antigens.
Moreover, the temporally restricted APC function of
BMMC indicates a flexibility of mast cells in playing a
role in CD4 T-cell dichotomy and/or sustaining CD4 T-
cell activation.
Methods
Reagents and chemicals
OVA323-339  (OVAp; ISQAVHAAHAEINEAGR) and
pigeon cytochrome c peptide (PCCP; KAERADLIAY-
LKQATAK) were synthesized on a Rainin Symphony
(Peptide Technologies, Tucson, AZ) synthesizer. Rabbit
anti-histamine antibody and Texas red-strepavidin were
purchased from Sigma (ST. Louis, MO). [3H]-thymidine
was purchased from Amersham. The T cell hybridoma
lines used include: 1) 3Do-54.8, which was provided by
Dr . P . Marrack at University of Colorado (Denver , CO)
and 2) AD10, restricted to PCC88-104 (PCCP) and IEk,
which was obtained from Dr. S. Hedrick at University of
California at San Diego. A20 (H-2d) and DECK.ICAM
(H-2k), which were originally transfected with I-Ek by Dr.
R. Germain, NIH, and further transfected with ICAM-1
by Dr. P. Kuhlman, La Jolla Cancer Research, were
employed as APC.
Recombinant GM-CSF and IL-3 were purchased from
Genzyme Corp. (Cambridge, MA). TNP-OVA and DNP-
specific IgE prepared from IgE-secreting hybridoma,
26.82 were prepared in our laboratory as described [10].
Antigen-IgE complexes were prepared by incubating
TNP-OVA and IgE at the same concentrations (wt/wt)
for 30 min at room temperature. The following reagents
were purchased from BD PharMingen (SD, CA): MAbs
anti-B220/CD45R (RA3-6B2), anti-IAd (39-10-8, IgG3/κ),
anti-IEk (17-3-3, IgG2a/κ), anti-CD16/32 (2.4G2), anti-
CD54 (ICAM-1, 3E2), anti-CD49d (integrin α4, R1-2),
anti-CD29 (integrin β1, Ha2/5), anti-CD11a (integrin αL,
LFA-1 α chain, 2D7), allophycocyanin-conjugated anti-
mouse c-kit/CD117 (2B8), FITC-murine control mono-
clonal IgG1, PE-murine control mIgG1, FITC-rat mIgG1
control and FITC-streptavidin. Anti-CD11c (N418) was
obtained from Miltenyi Biotec (Auburn, CA). Hybridoma
F4/80 secreting MAb directed against macrophages/
m o n o c y t e s ,  i s  a  g e n e r o u s  g i f t  f r o m  D r .  S .  G o r d o n  a t
Oxford University [11]. Hybridomas secreting MAb anti-
FcεRI (TW) was obtained from the laboratory of Profes-
sor David Holowka at Cornell University (Ithaca, NY).
The MAb was previously shown by us to bind to FcεRIα
[12]. FITC conjugate of TW was prepared in the labora-
tory. WEHI-3 constitutively secreting IL-3 was provided
by Dr. J. W. Schrader at the University of British Colum-
bia (Vancouver, Canada), and D11 hybridoma secreting
I L - 3  w a s  p r o v i d e d  b y  D r .  N .  A r a i  a t  D N A X  R e s e a r c h
Institute (Palo Alto, CA). Recombinant SCF was obtained
from Dr. T. Huff (Virginia Commonwealth Univ, Rich-
mond, VA) [13]. To perform depletion of putative con-
taminating APC, the reagents were purchased from
Miltenyi Biotec (Auburn, CA): anti-B220, and F4/80 anti-
macrophage/monocytes, and anti-CD11c (N418 for DC)
and mouse anti-rat kappa light chain (MAR18.5) coupled
t o  m a g n e t i c  M i c r o B e a d s ™ .  P r o c e d u r e s  w e r e  f o l l o w e d
according to this vendor.
BMMC cultures and differential staining
Femurs were collected from three to six-week old female
DBA/2 (H-2d), BALB/c (H-2d) or C3H (H-2k) mice (Jack-
son Lab, Bar Harbor, ME). Marrows were compressed out
from the bone cavities with a steady stream of RPMI from
a syringe fitted with a 27-gauge needle. Cells were gently
spread out and cultured in two 75-flasks in 20% WEHI-3-
or D11-conditioned medium in 10% fetal bovine serum
(FBS). Non-adherent cells were transferred weekly to a
new flask and supplemented with fresh medium. The
purity of three-week old mast cell cultures was estab-
lished by the following assays.
Histamine assay: 5 × 104 cells were prepared onto a
cytospin slide, air dried, fixed in 3% paraformaldehyde for
10 min, washed, and permeabilized in 0.2%Triton X-100/
PBS for 2 min. One hundred μl of control rabbit IgG or
rabbit anti-histamine at 1:100 dilution (Sigma, ST. Louis,
MO) were added and the slide was placed in a moist
chamber for 2 hr. Slides were washed and followed by
addition of 100 μl of biotinylated oat anti-rabbit IgG at
1:1000 and Texas red-strepavidin at 1:100.
Metachromatic toluidine blue staining: 5 × 104 BMMC
were prepared onto a cytospin slide, air dried, and treated
with Mota's fixatives for 10 min, followed by 70% ethanol.
Slides were washed with distilled water and treated with
acidic toluidine blue solution for 10 min, followed by 66%
and 100% ethanol, and finally air-dried and mounted. The
magnification was at 200 and 1000, respectively with 20×
and 100× objectives
Zymosan ingestion: Less than 1% of cells in BMMC cul-
tures ingested opsonized zymosan particles, after incuba-
tion for 1 hr at a zymosan concentration of 1,600 μg/106
cells, as assessed by Giemsa staining [14], an indication of
macrophage contamination.
Purification of BMMC by magnetic beads
Three-week old BMMC were cultured in 20% WEHI-3-
conditioned medium and stimulated with GM-CSF at 100
U/ml with or without supplement of IL-4 at 100 U/ml.
About 98-99% of cells were stained positive by toluidineGong et al. BMC Immunology 2010, 11:34
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blue, and less than 1-2% of cells were positive by MAbs
anti-B220/CD45R (B cells), anti-F4/80 (macrophages/
monocytes) or anti-CD11c (DC). Three week old BMMC
at 5 × 106 cells/ml in the bulk cultures of 5 × 108 cells,
were treated with 2.5 μg/ml anti-B220 and anti-F4/80 fol-
lowed by mouse anti-rat kappa light chain (MAR18.5)
coupled to magnetic MicroBeads™ (Miltenyi Biotec) and
then passed through anti-CD11c coupled directly to mag-
netic beads. BMMC undergoing two negative selections
were considered pure mast cells. Columns were thor-
oughly washed, and the adherent cells bound to the beads
were harvested.
BMMC and APC/T cell hybridoma cocultures
To employ as a source of APC, BMMC were primed with
recombinant GM-CSF (100 U/ml) overnight prior to har-
vest. In some experiments, BMMC were then negatively
selected by passing through affinity antibody-coupled
magnetic beads as described above, and the optimal
ratios of BMMC to T-cells were determined to be from
102 to 105. Routinely, 1 × 105 BMMC were incubated with
1 × 105 T cell hybridoma cells (restricted for OVA peptide
and I-Ad) in the presence of IgE-TNP-OVA complexes,
TNP-OVA conjugate, native OVA protein or OVA323-339
peptides; or with AD10 T cell line (restricted for PCCP
peptide and I-Ek) in the presence of PCCP for 48 to 72 hr
for optimal levels of IL-2 production. Alternatively,
BMMC (1 × 105 cells) were pulsed with the above anti-
gens overnight, washed, and added to 1 × 105 3Do-54.8
without further antigen addition. Levels of IL-2 secreted
by 3Do-54.8, or AD10 were quantified by a bioassay that
measures [3H]-thymidine incorporation by IL-2-depen-
dent NK-3 cells. Supernatants were routinely harvested
after 48 hr of incubation, and IL-2 content was assessed
as followed. Thirty μl of supernatant from each sample
were added to 104 IL-2 dependent NK-3 cells for 48 hr.
One μCi of 3H-thymidine was added to NK-3 cultures
overnight before cell harvest. Incorporation of 3H-thymi-
dine was determined by a β-counter. Data were expressed
as means and standard deviations of CPM (counts per
minute) of triplicate or quadruplicate 96 well cultures.
Sorting by flow cytometry
Cells were harvested from three-week old BMMC cul-
tures. Approximately, 20 × 106 cells were harvested from
three-week old BMMC cultures, resuspended at 106/ml.
Cells were incubated at 4°C with 1 μg/ml MAb FITC-
anti-FcεRIα (clone TW, rat MAb IgG, a gift of Dr. David
Holowka, Cornell Univ) for 45 min, washed and har-
vested. Flow cytometric sorting experiments were per-
formed using a FACS III cell sorter (Becton-Dickinson,
Sunnyvale, CA). An argon ion laser (Model 164-05, Spec-
tra-Physics) was used at a power of 300 mW and an exci-
tation wavelength of 488 nm. FITC (green) fluorescence
was detected by a combination of a 520 nm long pass and
a 540 nm short pass filter. Sorting was carried out using
standard three-droplet deflection criteria with a 70 μm
nozzle at the rate of analysis of ~300 cells/s. About 10 ×
106 cells were sorted via one continual operation over-
night. Sterilization of the tubing system was performed
with 70% ethanol. FcεRI(+) cells were then sorted by flow
cytometry by a stringent cut-off point into FcεRIhi (2-3
log intensity) vs FcεRIlo (0-1 log intensity) population.
Next, 1 × 105 FcεRIhi/MHCII(+) cells or FcεRIlo /MHCII(-
) cells were incubated with 105 3Do-54.8 T cell hybrido-
mas in the presence of different concentrations of IgE-
TNP-OV A, TNP-OV A or IgE (A, B) as well as OV A or
OVA peptide (C) for 72 hr. Supernatants were then har-
vested and levels of IL-2 were tested for [3H]-thymidine
incorporation by IL-2-dependent NK-3 cells.
FACS analysis of cell surface and intracellular staining
For viable cell staining, 1 × 106 cells were resuspended in
100 μl medium containing MAbs at 1-2 μg/ml at 4°C for
30 min, washed, and fixed with 2% paraformaldehyde. For
two-color staining for FcεRIα and surface MHC II, cells
were incubated with FITC-anti-FcεRIα(TW) and PE-
anti-IAd. For two-color staining for differentiation of
mast cells and basophils, three week old BMMC were
stained are incubated with FITC anti-FcεRIα(TW) and
PE-anti-mouse c-kit/CD117 (2B8). For intracellular stain-
ing, cells were first fixed in 2% paraformaldehyde in Dul-
becco-PBS (D-PBS) for 20 min at 4°C. Cells were then
washed twice with permeabilization buffer (0.1% saponin
in D-PBS without Mg2+/Ca2+, 1% FBS), and stained cells
with FITC- anti-FcεRIα (TW) and PE-anti-IAd. FACS
analysis was performed on a FACScan (Becton Dickin-
son). Ten thousand events were collected and analyzed by
CELLQuest program (version 1.2.2).
Results
Pure BMMC depleted of professional APC present antigens 
and are more efficient via FcεRI-mediated antigen uptake
BMMC cultured in IL-3 for three weeks were shown to
present antigen (9). It is critical to ascertain whether
BMMC cultures contain pure mast cells without contam-
inating APC cell types. Nearly all the cells in the cultures
were mast cells as ascertained by intracellular histamine
staining (Fig. 1: Panels b and e vs a and d). Because mac-
rophages that internalize histamine may also be stained
positive [15], the ubiquitous presence of abundant
metachromatic granules characteristic of mast cells, was
then ascertained by toluidine blue staining (Fig. 1: Panels
c and f).
Fig. 1g showed that 98.7% of BMMC (90.84% in the
third quadrant plus 7.85% in the second quadrant, Fig. 1:
Panel g) exhibited surface receptors for stem cell factor
(c-kit, CD117), indicating these cells are of the mast cellGong et al. BMC Immunology 2010, 11:34
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and not basophil lineage, and apparently all surface c-kit
+ BMMC also exhibited surface high affinity IgE Fc
receptors delineated by two color FACS (Fig. 1: Panel g).
It was previously reported that a minor subset of FcεRI +
mast cells, exhibiting surface c-kit, exists in IL-3/SCF
containing bone marrow cultures [16]. Thus 0.38% cells
(of the fourth quadrant) exhibiting surface FcεRI but not
c-kit, may either belong to the putative basophils or to an
early lineage mast cells.
Due to the presence of approximately 1% residual cells
devoid of mast cell markers, we therefore proceeded to
determine whether purified BMMC, negatively selected
by adsorption on MACS columns with anti-B220, anti-
F4/80 and anti-CD11c, can still present antigens.
As shown in Fig. 2A, pure mast cells, depleted of con-
taminating B-cells, monocytes, and dendritic cells were
fully capable of antigen presentation. Mast cells treated
with IgE-TNP-OVA complexes were more effective in
antigen presentation than those treated with TNP-OVA
alone. Approximately four-fold enhancement of 3H-thy-
midine incorporation was observed with mast cells
treated with 0.1 μg/ml IgE-TNP-OVA as compared to
those treated with similar dose of TNP-OVA. Moreover,
close to two-fold enhanced 3H-thymidine uptake was
observed in mast cells treated with 1 μg/ml IgE-TNP-
OVA as compared to those treated with TNP-OVA, while
the difference in efficacies of presenting IgE complexes vs
haptenated antigen alone, was not noticeable in higher
dose range from10 to 100 μg/ml. Purified BMMC were
also able to process and present native OVA as well as
present OVA peptide to T cells (Fig. 2B and Fig. 2C). On
the other hand, mast cells were inefficient in presenting
antigens at levels from 0.001 to 0.01 μg/ml (not shown).
Next, to prove the less than 1% contaminating cells
were indeed effectively removed, adherent cells, physi-
cally separated from pure mast cells, eluted from MACS
columns in the same experiment of these bulk cultures,
were then examined for APC function. As shown in Fig.
2D and Fig. 2E, B cells/macrophages and dendritic cells
were potent in presenting different forms of antigens.
And as anticipated, similar efficacy of antigen presenta-
tion was observed in these contaminating APC, treated
with IgE antigen complexes vs haptenated antigens, indi-
cating FcεRI-mediated antigen focusing did not play a
role in these professional cell types. Taken together, these
experiments showed that residual contaminating APC
exhibiting the respective APC surface markers and APC
function, were indeed effectively removed from the
three-week BMMC cultures; and that mast cells, even
purer than the starting highly pure c-kit + mast cells,
were still fully capable of antigen presentation in the
absence of contaminating APC.
Next, we evaluated efficacies of antigen presentation at
a more extensive titration of mast cells to T-cell ratios as
compared to contaminating professional APC, recovered
from the MACS columns, on a cell-to-cell basis. As
shown in Fig. 2F, significant T-cell responses were stimu-
lated by all three types of cells, B-cells/monocytes, DC
and mast cells from a range of 1 × 105 to 2.5 × 102, added
to 1 × 105 T-cell hybridomas, i.e., at APC to T-cell ratios
Figure 1 Characterization of three-week old BMMC cultures. Histamine staining: slides treated with rabbit IgG (Panel a, d) vs rabbit anti-histamine 
(Panel b, e). Toluidine blue staining: 5 × 104 BMMC were prepared onto a cytospin slide, examined respectively with 20× (Panel c) and 100× objectives 
(Panel f). Surface FcεRI and c-kit expression: BMMC were stained with PE-anti-c-kit and FITC-anti-FcεRI analyzed by flow cytometry. Numerically, 98.7% 
c-kit + cells are mast cells, including c-kit +, FcεRIhi cells (quadrant 3, 90.84%), and c-kit +, FcεRIlo cells (quadrant 2, 7.85%) (g). The procedures were 
described in Materials and methods.Gong et al. BMC Immunology 2010, 11:34
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from 1:1 to 0.0025:1. Quantitative CPM reduction was
proportional to the number of input APC and T-cell
ratios from 1:1 to 0.2:1. In contrast, CPM incorporation
was diminished impressively at the 'inflexion' point
noticed at 4 × 103 input APC to T-cell ratio at 0.1:1. Fur-
thermore, precipitous fall in CPM counts around back-
ground levels was noticed at 2 × 103 input APC to T-cell
ratio at 0.04:1. Because a typical in vitro BMMC culture
set at 1:1 APC to T-cell ratio, the contaminating APC,
when present, fell below 103 per culture, the possibility of
contaminating APC henceforth was responsible for anti-
gen presentation in the three week old BMMC cultures,
can be formally ruled out.
Thus the above data show four pertinent points for
mast cells as APC: (i) pure mast cells were indeed capable
of antigen presentation; (ii) pure mast cells were equally
potent APC as compared to professional APC: B-cells/
monocytes and DC; (iii) it is unlikely that contaminating
cells at ~1% levels in the three week BMMC were respon-
sible solely for antigen presenting capacity; (iv) it also fol-
lows that it is unlikely that the 0.38% surface FcεRI +/c-kit
negative cell subset, even if they represent the basophils,
can not be responsible for antigen presentation in the
BMMC cultures.
Augmented antigen presentation via IgE-antigen com-
plexes, as shown in the above Fig. 2A, suggests an impor-
t a n t  r o l e  o f  I g E - d e p e n d e n t antigen presentation via
FcεRI-mediated pathway. To block FcεRI receptor-medi-
ated antigen presentation, BMMC were preincubated
with anti-ragweed IgE at 100 μg/ml for one hr at 37°C
p r i o r  t o  a d d i t i o n  o f  I g E - T N P - O V A  a t  1  μ g / m l .  F i g .  3
showed that the capacity of IgE-TNP-OVA-treated mast
cells to stimulate T cells was significantly reduced after
treatment with anti-ragweed IgE. These results support
the notion that FcεRI on BMMC plays an important role
in antigen presentation.
FcεRIhi but not FcεRIlo subset of three-week old BMMC is 
capable of MHC II-mediated antigen presentation
The augmented antigen-presenting pathway via FcεRI
prompted the hypothesis that the BMMC subset express-
ing high levels of FcεRI (i.e., mean fluorescence intensity
of two to three logs by flow cytometry) may also express
Figure 2 BMMC cultures depleted of contaminating APC were fully capable of antigen presentation. 1 × 105 pure BMMC depleted of B cells/
macrophages or DC were incubated for 72 hr with 105 3Do-54.8 in the presence of IgE-TNP-OVA, TNP-OVA (Panel A), OVA (Panel B) or OVA peptide 
(Panel C). The residual contaminating APC eluted from the anti-B220/F480 and CD11c MACS columns from bulk cultures (~2 × 108 cells in order to 
harvest around 1% contaminating cells for experiments), were prepared. 0.4 × 105 B cells/macrophages (Panel D) or 0.4 × 105 DC (Panel E) were incu-
bated for 72 hr with 105 3Do-54.8 in the presence of IgE-TNP-OVA, TNP-OVA, OVA, or OVA peptide. Next, in the titration experiment, pure mast cells 
were similarly prepared as above by MACD columns, along with column eluted, residual contaminating APC of these bulk cultures. The different cell 
types were then incubated with 105 3Do-54.8 in the presence of OVA peptide, at a APC to T-cell ratios ranged from 1:1 to 0.0025:1 at a serial 2- to 2.5-
fold dilutions (Panel F). Levels of IL-2 in 72 hr supernatants were determined by stimulating 3H-thymidine incorporation and proliferation of IL-2 de-
pendent NK-3 cells as described in Material and methods.Gong et al. BMC Immunology 2010, 11:34
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high levels of cell surface MHC II. As shown in Fig. 4A,
one subset of FcεRIhi subset of BMMC exhibited high lev-
els of cell surface FcεRI and MHC II; this subset of FcεRI/
MHC II high cells was delineated in quadrant 3 (35%),
and 4b (13.5%) with a subtotal of 48.5% pure mast cells.
Moreover, the FcεRIlo subset exhibited lower but signifi-
cant level of cell surface FcεRI, devoid of surface MHC II,
i.e., FcεRIlo/MHC II(-) cells, delineated in quadrant 1a
and 1b with a subtotal of 50.8%. Therefore, FcεRIhi and
FcεRIlo constituted approximately 99% mast cells with or
without expressing surface MHC II. Only 0.6% FcεRIhi
cells exhibited low levels of surface MHCII in quadrant 2,
and very few (~0.01%) FcεRIlo cells exhibited high level
surface MHC II.
In striking contrast, Fig. 4B showed that despite the dif-
ferential expression of cell surface FcεRI and MHC II
between these two distinct subsets of mast cells, almost
all BMMC exhibited high levels of intracellular FcεRI,
indicating their mast cell lineage. Interestingly, in con-
trast to cell surface expression, nearly all mast cells exhib-
ited intracellular MHC II, while 87% of the mast cells
exhibited high levels of intracellular MHC II with 12%
mast cells exhibiting lower level of MHC II. Furthermore,
as anticipated, surface FcεRIhi/MHC II + mast cell subset,
compared to surface FcεRIlo/MHC II(-) subset, exhibited
higher levels of adhesion molecules, LFA-1α, ICAM-1,
and α4 integrin and β1 integrin (data not shown).
In summary, the above data demonstrated two points:
(i) ubiquitous expression of the FcεRI marker of the
receptor α chain (detected by MAb TW) intracellularly
ascertained the mast cell lineage of BMMC culture; (ii)
distinction of mast cell subsets is made according to dif-
ferential surface expression but not intracellular expres-
sion of the two employed markers, FcεRI and MHC II.
The aforementioned observations then prompt the
hypothesis that subset of FcεRIhi mast cells, expressing
high levels of MHC II, is competent in antigen presenta-
Figure 4 Delineation of surface vs intracellular FcεRI/surface MHC II+ cells in three-week old BMMC. For viable cell staining, 1 × 106 three-week 
old mast cells were stained with FITC-anti-FcεRIα (TW) and PE-anti-IAd at 10 μg/ml and fixed with 1% paraformaldehyde. Panel A: FcεRI + cells were 
divided into FcεRIlo (below 0.8 to the second log TW intensity), and FcεRIhi cells (between second and third log TW intensity). Accordingly, quadrant 
#2 (.6%), #3 (35%) and #4b (13.5%) amounted to 49.1% FcεRIhi cells. By contrast, quadrant 1a (9.8%) and #1b (41%) amounted to 49.8% FcεRIlo cells. In 
total, ~99% cells were FcεRI + cells. Panel B: To determine intracellular distribution, cells were prefixed, permeabilized, and stained. Quadrant percent-
ages were: quadrant #1 (.5%), #2 (12%), #3 (87%), and #4 (0.5%). Approximately 99% cells were FcεRIhi mast cells, and 87% of these mast cells also ex-
hibited high levels of intracellular MHC II.
Figure 3 Block of surface FcεRI-mediated antigen focusing and 
presentation of anti-DNP IgE/TNP-OVA by ragweed-specific IgE. 
BMMC were preincubated with anti-ragweed IgE at 100 μg/ml for one 
hr, washed and, followed by addition of IgE/TNP-OVA complexes, and 
coincubated with 3Do-54.8. Levels of IL-2 in 72 hr supernatants were 
determined by stimulating 3H-thymidine incorporation and prolifera-
tion of IL-2 dependent NK-3 cells as described in Material and meth-
ods.Gong et al. BMC Immunology 2010, 11:34
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tion, while subset of FcεRIlo mast cells, lacking cell surface
MHC II, is incapable of antigen presentation. Next,
BMMC were differentially sorted into the surface FcεRIhi
vs. the FcεRIlo subset according to the surface intensity by
MAb anti-FcεRIα(TW). Sorted surface FcεRIhi subset of
BMMC was capable of presenting all three form of anti-
gens (Fig. 5), and as anticipated, this subset of BMMC
was more efficient in presenting IgE-TNP-OVA as com-
pared to haptenated OVA, native OVA (Fig. 5A) and pep-
tide antigen (Fig. 5C). In contrast, purified surface FcεRIlo
subset, also lacking surface expression of MHCII, was
incapable of presenting IgE-TNP-OVA (Fig. 5A), TNP-
OVA (Fig. 5B), and OVA peptide (Fig. 5C). It is pertinent
to point out that the contaminating residual APC that do
not express FcεRI, should have been enriched in the
FcεRIlo subset. Thus, the conspicuous absence of antigen-
presentation function in this BMMC subset indicates and
substantiated the fact that the contaminating APC can
not account for antigen presentation in BMMC/T-cell
hybridoma cocultures.
Consequently, we tested whether blocking surface
MHC II of the FcεRIhi antigen-presenting BMMC subset
inhibited antigen presentation. As shown in Fig. 6, addi-
tion of MAb anti-IAd profoundly inhibited IgE-depen-
dent antigen presentation at 1 to 100 μg/ml IgE-TNP-
OVA (Fig. 6A). Treatment with anti-IAd  also potently
diminished antigen presentation of both native OVA pro-
tein and OVA peptide (Fig. 6B and Fig. 6C). In contrast,
MAb against an irrelevant specificity, i.e., anti-IEk (17-3-
3) did not affect the antigen presenting function of
BMMC (not shown).
The antigen-presenting function of BMMC is diminished 
upon extended culture
Next we examined whether 4 to 6 week-old BMMC
(DBA/2 mice, H-2d) can also present antigen Surprisingly,
as shown in Table A1A, IL-3 cultured, 4-week old BMMC
were incapable of presenting OVA, TNP-OVA, and the
OVA peptide. The source of the IL-3 as growth factors
did not make a difference, since BMMC cultured in the
presence of IL-3-containing conditioned medium from
D11 cells, recombinant IL-3 (100 U/ml), primed with
GM-CSF all lacked antigen-presenting capacity. Under
physiological conditions, stem cell factor (SCF) stimu-
lates mast cell progenitors of various tissue origins to dif-
ferentiate more toward a mature phenotype of connective
tissue mast cells [5-7]. As shown in Table A1A, BMMC
cultured with SCF (1 μg/ml) or a combination of SCF and
IL-3 still failed to present antigen. Moreover, BMMC
treated further with IL-4 (100 U/ml) [9] did not render
four-week old BMMC competent in antigen presentation.
In  c on t ras t,  t hr ee -wee k o ld B MM C  as  pos it ive  c on t r ol
were consistently capable of presenting different forms of
antigens regardless supplementation of IL-3 or SCF or
priming by IL-4. Furthermore, four-week old BMMC pre-
pared from another H-2d haplotype, BALB/c mice, were
likewise not capable of antigen presentation (data not
shown).
We then extended the study to APC function of BMMC
prepared from B10.BR mice (H-2k) of a different MHC
haplotype. As also shown in Table A1A, four-week old
BMMC failed to present PCC, TNP-PCC, and IgE-TNP-
PCC to PCCP-specific AD10 T-cell line [17]. Moreover,
these BMMC were not rendered competent in antigen
presentation by additional IL-4 treatment [18]. The lack
of antigen-presenting function by 4-6 weeks old pure
BMMC was consistently observed in fifteen experiments
over 12 months. Moreover, Table B1B showed that the
loss of antigen-presenting function occurred precipi-
tously in the midst between the third and fourth weeks on
day 26 in the same cultures. The loss of antigen present-
ing function was not due to loss of adherent cell popula-
tion since media were not decanted nor the cells
transferred to a new dish. These observations indicate a
unique temporally restricted antigen-presenting capacity
inherent in bone marrow derived mast cells. In contrast,
the antigen-presenting function of the purified residual
professional APC were fully functional throughout the
entire 3-week 3 to 6-week cultures (not shown).
Discussion
Herein, the study shows that highly pure mast cells from
three week old, IL-3-containing bone marrow cell cul-
tures indeed present antigens after depletion of ~1% con-
taminating APC. This study also provides the novel
observations: (i) two subsets of BMMC are delineated;
one subset expressing both surface high levels of FcεRI
and high surface MHC II, while another expressing low
levels of surface FcεRI with non-detectable levels of sur-
face MHC II. Nevertheless, the intracellular expression of
both biomarkers are equivalent in all BMMC; (ii) the
purified FcεRIhi BMMC subset that express high levels of
surface MHC II, is competent in antigen presentation,
while the FcεRIlo subset can not present antigens. Since
FcεRIlo was presumably enriched even 2-fold for the puta-
tive contaminating APC, its conspicuous lack of capacity
for antigen presentation strongly argues against the role
of contaminating professional APC for stimulating T-cell
hybridomas in BMMC/T-cell cocultures; (iii) augmented
IgE-dependent antigen presentation pathway in the
FcεRIhi subset is inhibited by IgE of a different specificity,
and the APC function is blocked by anti-MHC II anti-
bodies; (iv) the APC function is also temporarily
restricted to the three weeks old BMMC, and is irrevoca-
bly lost in further extended cultures.
Previously, Mecheri and colleagues showed BMMC
cultured in ConA-conditioned media or two-way mixed
lymphocyte reaction (MLR) supernatant present antigensGong et al. BMC Immunology 2010, 11:34
http://www.biomedcentral.com/1471-2172/11/34
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Figure 5 Surface FcεRIhi/MHCII(+) BMMC but not surface FcεRIlo/MHCII(-) BMMC are capable of presenting antigens. Three-week old BMMC 
were sorted into FcεRIhi/MHCII positive vs FcεRIlo/MHCII negative subsets. Each BMMC subset was then incubated with 3Do-54.8 in the presence of 
IgE-TNP-OVA (Panel A), TNP-OVA (Panel B) and OVA peptide (Panel C), and levels of IL-2 in 72 hr supernatants were determined by stimulating 3H-
thymidine incorporation and proliferation of IL-2 dependent NK-3 cells as described in Material and methods.Gong et al. BMC Immunology 2010, 11:34
http://www.biomedcentral.com/1471-2172/11/34
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Figure 6 Anti-IAd potently inhibits antigen presentation by BMMC (H-2d). 106 BMMC were treated with 10 μg/ml MAb anti-IAd for 30 min at 4°C. 
105 treated BMMC were then incubated with 1 × 105 3Do 54.8 in the presence of IgE-TNP-OVA (Panel A), OVA (Panel B) and OVA peptide (Panel C). 
Levels of IL-2 in 72 hr supernatants were determined by stimulating 3H-thymidine incorporation and proliferation of IL-2 dependent NK-3 cells as de-
scribed in Material and methods.Gong et al. BMC Immunology 2010, 11:34
http://www.biomedcentral.com/1471-2172/11/34
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Table 1: A - Three-week but not four-week old BMMC are capable of antigen presentation and B - Loss of APC function 
between three and four week old BMMC
A
DBA/2 (H-2d) Culture conditions Antigenic stimulation (SI)
3Do-54.8
Background (CPM)
4 week old BMMC, GM-CSF primed OVA OVAp IgE-TNP-OVA None
WEHI-3 0.74 1.1 .95 1,504
D11 sup .86 .76 .58 2,045
Rec IL-3 .75 .80 .63 1,786
SCF 1.3 .67 .75 1,745
WEHI-3+SCF .95 .87 1.0 3,164
WEHI-3+IL-4 .79 .83 .87 2,568
3 week old BMMC, GM-CSF primed
WEHI-3 7.8* 8.5* 14.4* 2,359
SCF 10.5* 9.6* 15.2* 2,790
WEHI-3+IL-4 8.5* 7.4* 22.3* 3,876
B10.BR (H-2k) Antigenic stimulation (SI)
AD10
None
4 week old BMMC GM-CSF primed PCC PCCP IgE-TNP-PCC
WEHI-3 sup 1.4 1.3 0.8 2,140
+IL-4 1.2 1.3 .9 1,398
3 week old BMMC, GM-CSF primed
WEHI-3 14.4* 9.8* 18.2* 2,575
+IL-4 15.2* 12.1* 17.4* 2,132
BGong et al. BMC Immunology 2010, 11:34
http://www.biomedcentral.com/1471-2172/11/34
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to stimulate CD4 + helper T cells [9,19]. However, there
has been continual debate concerning the purity of
BMMC and the role of possible contaminating APC. Our
previous study in collaboration with Stevens, Austen and
colleagues [14,20] also showed three-week old BMMC
grown in WEHI-3-conditioned media were authentic
m a s t  c e l l s  b y  EM  s t u d i e s,  gr a n u l a r  c o n t e n t,  as  w e l l  a s
release of histamine, PDG2 and leukotrienes via IgE-
mediated cell activation. The present study also confirms
the granularity and histamine content in almost all the
cells in three-week old BMMC cultures. Approximately
98.7% BMMC expressed high density of c-kit and high vs
low density of surface FcεRI (Fig. 1g and Fig. 4A), and
nearly all these BMMC uniformly exhibited high levels of
FcεRIα in the cytosol (Fig. 4B).
Basophils, present in less than 1% circulating leuko-
cytes were recently shown to play a critical role in innate
immunity and especially in orchestrating Th2 commit-
ment [21]. Although the present culture system did not
support basophils, a possible low contamination (~0.38%)
can not be excluded [16]. Since antibodies to CD200R3
(Ba91 and Ba103) directly activate degranulation of baso-
phils as well as mast cells in vitro [21-24], these antibod-
ies may not be directly employed for depleting minor
contaminating basophils in BMMC cultures without a
concomitant modulatory effect on antigen presentation
by mast cells. On the other hand, these antibodies
appeared to eliminate preferentially basophils in vivo.
Thus, future studies may be conducted in vivo for evalu-
ating antigen-presenting function of adoptive transferred
BMMC, while preferentially depleting basophils in situ in
an appropriate animal model deficient in mast cells as
well as all the other professional APC cell types. This
study also relies on supply of a large quantity of antibod-
ies produced by hybridoma clones, available to the
research laboratory [21-24].
Herein, we formally showed that physically purified,
surface FcεRIhi but not the cell surface FcεRIlo (or null)
BMMC subset present antigens. Noteworthily, these
sorted surface FcεRIlo BMMC are also authentic mast
cells according to the abundant expression of the lineage-
specific FcεRIα marker in the cytosol [25,26] (Fig. 4B) and
DBA/2 (H-2d) Culture conditions Antigenic stimulation (SI)
3Do-54.8
Background (CPM)
Days old of 
BMMC
GM-CSF primed, in WEHI-3 
media
IgE-TNP-OVA None
Day 22 ibid. 10.8* 1,799
Day 23 ibid. 12.1* 1,325
Day 24 ibid. 14.5* 2,569
Day 25 ibid. 12.6* 1,634
Day 26 ibid. 3.3* 2,788
Day 27 ibid. 0.86 2,961
1A: BMMC (H-2d, or H-2k) were prepared by culturing bone marrow cells in the presence of different sources of IL-3 (20% supernate) or SCF (1 μg/
ml) for three or four weeks with weekly decanting of adherent cells. BMMC were primed with GM-CSF (100 U/ml) for 48 hr and some cultures in 
addition treated with IL-4 at 100 U/ml. BMMC (H-2k) and PCCP-specific AD10 T-cell line were stimulated with pigeon cytochrome c (PCC), PCC 
peptide (PCCP) or IgE-TNP-PCC complexes at 10 μg/ml for 48 hr and IL-2 production was determined. 1B: For daily assessment of APC function 
from day 22 to day 27 of the fourth week, nonadherent BMMC were directly obtained from the WEHI-3 supplemented culture wares in the fourth 
week culture (Day 22 to Day 27) without culture media or plate change. Background CPM was determined in cocultures of differently-treated 
BMMC plus T cells without antigen stimulation. Stimulation index (SI) was computed as quotients of total CPM of 3H-thymidine uptake of the 
antigen-stimulated cultures over nonantigen-stimulated controls. Triplicates were set for each group of stimulation and the non-stimulated 
control, and the means and SE were computed and two-tailed t-test of the antigen-stimulated group compared to background CPM was 
performed; SE of all observations were calculated within 15% of the computed means. To simplify data, SI with p values < 0.01 was denoted as a 
* marks in cocultures with competent BMMC stimulation. SI of the group without the mark indicated a failure or loss of antigen presentation by 
extended cultured mast cells. L-2 secreted in the coculture supernatants was determined by stimulating proliferation and 3H-thymidine uptake 
of IL-2 dependent NK3 cell line.
Table 1: A - Three-week but not four-week old BMMC are capable of antigen presentation and B - Loss of APC function 
between three and four week old BMMC (Continued)Gong et al. BMC Immunology 2010, 11:34
http://www.biomedcentral.com/1471-2172/11/34
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surface c-kit (Fig. 1g) [16]. Residual contaminating pro-
fessional APC did not play a role in these BMMC cultures
for three reasons: (i) three week old BMMC depleted of
contaminating APC were fully capable of antigen presen-
tation (Fig. 2A-C); (ii) surface FcεRIlo BMMC, presumably
e n r i c h e d  f o r  t h e  p u t a t i v e  p r o f e s s i o n a l  A P C ,  w e r e  n o t
capable of antigen presentation; (iii) purified professional
APC added to T-cells at a simulated ratio of BMMC/T-
cell cultures, i.e., 103 contaminating APC to 105 T-cells,
failed to stimulate IL-2 production by T-cell hybridomas
(Fig. 2F).
Augmented presentation of antigen-IgE complexes can
be mediated via the low affinity FcεRII pathway [27].
Herein augmented presentation of antigen-IgE complexes
was mediated via the high affinity FcεRI pathway, blocked
by preincubation with monomeric ragweed-specific IgE.
Mast cells are increasingly known for downregulating a
variety of immune effector functions in skin graft rejec-
tion, protozoan infection and UVB-induced contact der-
matitis [28-30]. In addition to the straightforward
receptor blockade mechanism, the diminished antigen
presentation may be in part explained by suppression of
APC function due to receptor interactions with mono-
meric ragweed-specific IgE in contrast to multivalent
interactions with TNP-OVA-IgE.
It is not known why low levels of cell surface FcεRIα
correlated with lack of MHC II cell surface expression
(Fig. 4A). MIIC-like compartments were noted intracellu-
larly in mast cells [31]. It is possible that there exists a
special mechanism, co-transporting intracellular pools of
FcεRI and peptides/MHC II in the MIIC-like compart-
ment to the cell surface [31]. Alternatively, the lack of cell
surface expression of the alpha subunit of FcεRI may be
due to lack of intracellular expression of β/γ subunits
[25,26], while surface MHC II expression depends on
vesicular transport of MIIC compartments to cell surface
during BMMC differentiation. Since exosomes secreted
by RBL-2H3 can arm professional antigen presenting
cells [31,32], it remains possible that the FcεRIlo mast cell
subset may indirectly contribute to antigen presentation
via cross-presentation of secreted exosomes by other pro-
fessional APC [32,33].
The mechanisms for sudden collapse of APC function
of BMMC on day 26 BMMC and further extended cell
cultures of 4-6 week in vitro, are not unknown. Many
possibilities exist. It is interesting to speculate that con-
taminating basophils and/or professional APC from ~400
cells to 1,000 cells in the APC/T-cell cocultures may play
an indirect role in modulating competence of mast cells
in antigen presentation; and starvation of one or both cell
types in extended cultures may account for the tempo-
rally restricted nature of mast cells as a facultative APC
[28,34]. The elucidation of cellular and molecular mecha-
nisms underlying the spatiotemporally restricted nature
of pure mast cells as APC, remains a future challenge for
basic mast cell research and its clinical application.
Conclusions
Mast cells are increasingly known for modulating a vari-
ety of immune effector functions in skin graft rejection,
protozoan infection and UVB-induced contact dermatitis
[28-30]. The observation herein provides an additional
link for integrating inflammatory responses with spa-
tiotemporally restricted antigen presenting function via
IgE-dependent antigen presentation pathway in this
unique FcεRIhi /MHC II+ BMMC subset. Coupling anti-
gen presentation with secretory function of mast cells via
the interplay of cell surface FcεRI and MHC II can con-
tribute to important pathophysiological responses in
both innate and acquired immunity of the host
[24,28,34,35].
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